Impact of a multi-strain L. crispatus-based vaginal synbiotic on the vaginal microbiome: a randomized placebo-controlled trial

View Full Paper

Ask AI

Bookmark

The vaginal synbiotic significantly increased L. crispatus, achieving 90% conversion to CST I compared to 11% with placebo.
Increased L. crispatus and reduced Gardnerella vaginalis and Candida are key findings from the clinical trial.
Randomized placebo-controlled trial registered as NCT05659745 examined synbiotic impacts on the microbiome.
Results suggest potential for vaginal synbiotics to enhance microbiome health and reduce pathological microbes.

Discussion

No takes yet. Share an insight, caveat, or question.

Randomized trial shows increased L. crispatus in the vaginal microbiome compared to placebo, indicating synbiotic benefits.

Ravel et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark